"Pharmaceutical Speed Reading Society" No and weight loss new drugs approved in China clinical High announced personnel changes

December 17, 2020 / Medical Information List: Novartic oral supplement pathway inhibitors were recognized by the FDA breakthrough therapy; Novo Nord weight loss new drugs were approved clinically in China; Rongchang bio-anti-HER2 antibody association drugs are to be included in breakthrough treatment varieties; Zee-Pharma JAK inhibitors are eligible for FDA orphan drugs; Vico announces important personnel changes... Daily fresh medicine news, speed reading society and you pay attention to! Part 1 Policy Brief Jiangsu Province released the results of the procurement of the new crown vaccine December 15, Jiangsu Province Public Resources Trading Center issued the "Provincial Public Resources Trading Center on the publication of the results of the procurement of new coronavirus vaccine notice", Beijing Koxing Zhongwei Biotechnology Co., Ltd. and Beijing Institute of Biological Products Co., Ltd. won the bid, the winning bid price is 200 yuan.
the new coronavirus vaccine purchased only for emergency use of the new coronavirus vaccine in Jiangsu Province.
(Public Resources Trading Center, Jiangsu Province) Part 2 Watch Pfizer China and Keystone Pharmaceuticals reached a cooperation on December 16, Pfizer China and Keystone Pharmaceuticals held a strategic cooperation launch ceremony in Shanghai.
that Pfizer has been authorized by Keystone Pharmaceuticals to be solely responsible for the commercialization of the PD-L1 antibody drug Shugli monoantigen in China.
(Pharmaceutical Mission) China Resources Shuanghe acquired a 38.75 percent stake in Dongying Tiandong Pharmaceuticals today, China Resources Shuanghe announced that, according to the company's overall strategic plan, in order to further enrich cardiovascular anticoagulant products, access to anticoagulant technology platform, the company used its own funds to acquire 38.75 percent of Dongying Tiandong Pharmaceutical Co., Ltd., the purchase price of 341 million yuan.
(Sina Pharmaceutical News) China Resources 39 obtained an exclusive license for glioma innovation drug Greater China on December 16, China Resources 39 announced that it has reached an authorized cooperation with Oncoceutics to obtain exclusive development, production and commercialization rights for one of the latter's glioma innovative pharmaceutical products ONC201 in Greater China (Chinese mainland, Hong Kong, Macau, Taiwan).
the agreement, China Resources will make a down payment, milestone and sales credit to Oncoceutics.
Haizheng Pharmaceuticals obtained the exclusive marketing rights of microcore biosiglita sodium tablets in 19 provinces of China on December 16, Microcore Bio announced that its wholly-owned subsidiary Chengdu Microcore has signed an exclusive license and joint marketing strategy cooperation agreement with Haizheng Pharmaceuticals for Siglita sodium tablets, which will give the relevant intellectual property rights and exclusive drug marketing rights to Haizheng Pharmaceuticals in Chinese mainland designated regions (referring to 19 provinces such as Henan, Zhejiang and Jiangsu).
(Pharmaceutical Rubik's Cube) Vigo announced important personnel changes Recently, Shandong Weigao Group Medical Polymer Products Co., Ltd. issued the appointment of non-executive directors and executive directors and non-executive directors resignation announcement: Mr. Chen Lin has been appointed as a non-executive director of the Company; Appointed as a non-executive director of the Company, Mr. Bow Jianbo has resigned as an Executive Director of the Company with effect from 14 December 2020, and Ms. Chow Shuhua has resigned as a non-executive Director of the Company with effect from 14 December 2020.
(Cypress Blue Device) Part 3 Drug News Novartic's potential "first-in-class" oral supplement path pathrapy inhibitor was recognized by the FDA's Breakthrough Therapy Today, Novartic announced that the FDA has awarded its iptacopan (LNP023) breakthrough therapy for the treatment of bursts of sleep-based hemoglobinuria.
iptacopan was also identified as a rare pediatric disease to treat C3 renal ocytic disease.
Iptacopan is a potential "first-in-class" oral-specific alternative to complement pathway factor B inhibitors.
may be the first oral therapy to treat a variety of complementary-mediated diseases.
(Xinhua) -- Novartic's heavy heart failure drug, Nohinto, was supported by the FDA Advisory Committee to expand its scope of application, Novarda announced that the FDA's CRDAC voted 12 to 1 in support of the use of Entersto to treat patients with blood-test scores that preserve heart failure.
if approved by the FDA, Entresto could become the first treatment approved for HFpEF patients and the first to be approved for two major types of chronic heart failure.
(Drug Mingkangde) Novo Nord once a week subsuplision injection weight loss new drugs approved clinically in China On December 16, CDE's latest publicity Novo Nord AM833 obtained the default license for clinical trials, intended to be developed for weight management in obese/overweight patients.
AM833 is a new type of pancreatic amyloid polypeptide similar that Noor and Nord have developed once a week to inject subskin, whose primary function is to help slow food digestion and glucose release into the bloodstream.
AM833 can reduce weight by reducing food intake.
(Pharmaceutical Rubik's Cube) Novo Nordisk and Nordsomalutide Treatment Alzheimer's Disease Phase IIIa Trials Started December 16, Novo Nordisk announced that it will launch a key Phase IIIa research project on oral smeglutide (Somatroptide) for the treatment of Alzheimer's disease, involving approximately 3,700 patients with early Alzheimer's disease.
to assess differences in the efficacy and safety of placebos compared to oral smeglutide (14 mg, 1 time per day), the duration of the dose is expected to last approximately 2 years.
(Pharmaceutical Rubik's Cube) Amgen submitted a new drug application for KRAS G12C inhibitors today, Amgen announced that it has submitted to the FDA its application for a new drug in the study of KRAS G12C inhibitor sotorasib for the treatment of patients with local late stage or metastasis non-small cell lung cancer with KRAS G12C mutation.
(Immediate Drug News) oral therapy mastatinib reaches the primary clinical endpoint of Phase 2b/3 today, AB Science announced that it has reached its intended major endpoint in a phase 2b/3 clinical trial for the treatment of patients with mild and moderate Alzheimer's disease.
significantly improved changes in memory and cognitive indicators compared to placebos.
(Now) FDA approved the listing of immuno-optimized HER2 mono-antitherapy Margenza today, MacroGenics announced that the FDA has approved the listing of its immuno-optimized anti-HER2 monoclonal antibody Margenza (margetuximab-cmkb) in combination with chemotherapy to treat adult patients with metastasis HER2-positive breast cancer.
these patients have received two or more anti-HER2 programmes (at least one of which is to treat metastasis).
(Immediate Drug News) Osteoporosis new drug Aedes aeoporosis softgel was approved for listing in China on December 16, NMPA announced that the new drug Aedes aeoticol softgel developed by Roche's Japanese Chinese and foreign pharmaceutical co., Ltd. has been officially approved for listing in China.
, an active vitamin D3 derivative used to treat osteoporosis, according to public information released last week.
new data for the DETECT research project was released on December 16th, menarini Silicon Biosystems announced new data for the DETECT research project.
data were mainly focused on primary tumor biopsies and HER2 plus CTC in female patients with HER2-negative metastasis breast cancer.
that HER2-plus CTC screening of blood samples from these patients is an important tool for guiding treatment decisions and improving patient prognostication.
(AAP) Immunomodulation Vaccine was recognized by the FDA Breakthrough Therapy on December 15, IO Biotech announced that the FDA has awarded its development of a combination of tumor vaccines IO102 and IO103 anti-PD-1 monoantivirus non-excisive/metastasis melanoma breakthrough therapy eligibility.
data cut-off period, 45 percent of patients were fully relieved and 34 percent were partially relieved.
(Drug Mingkangde) Rongchang biological anti-HER2 antibody conceded drugs to be included in the breakthrough treatment varieties today, CDE official website of the latest publicity, Rongchang biological submission of "injection recombinant humanized anti-HER2 monoantigen-MMAE concedes" to be included in the breakthrough treatment varieties, the proposed adaptation for the past after the failure of chemotherapy progress of HER2 over-expression of local late stage or metastatic urethrial cancer patients.
(Pharmaceutical Mission) Zee-Pharma JAK inhibitor was qualified as an FDA orphan drug today, Zee-Pharma announced that it has been awarded orphan drug by the FDA for the treatment of bone marrow fibrosis in the development of the innovative chemical jactic acid tablets.
the drug is an selective kinase inhibitor that inhibits the non-subject tyrosine Janus-related kinases JAK1, JAK2 and JAK3.
(Pharmaceutical Mission) Henri Pharmaceutical PD-1 antibody two first-line therapeutic adaptation phase 3 clinical main study endpoint December 16, Hengrui Pharmaceutical announced that innovative drug injection carelli pearl monoantigen in two phase 3 clinical studies reached the main research endpoint: one for combined yew alcohol and cisplatin for advanced esophageal cancer first-line treatment;
(Pharmaceutical Mission) Qilu Pharmaceutical Malay acid Isola tablets the first review on December 16, the Official Website of the State Drug Administration shows that Qilu Pharmaceuticals' Malay acid Isola tablets through a consistent evaluation of supplementary applications.
Isola tablets for gastric mucous membrane protection agent, Qilu Pharmaceuticals for the first evaluation of the variety of enterprises.
(Minenet) Colum left oxyfluorosa star sodium chloride injection into the administrative approval stage recently, Colum according to the imitation of 4 categories of reported left oxyfluorosa star sodium chloride injection into the administrative approval stage, is expected to be approved and treated as a review.
2019, China's public medical institutions terminal left oxyfluorosa star sodium chloride injection sales of more than 600 million yuan.
(Minenet) Huiyu pharmaceutical yew alcohol injection into the administrative approval stage recently, Huiyu pharmaceutical according to the imitation of 4 categories of reported yew alcohol injection into the administrative approval stage, is expected to be approved recently and as reviewed.
2019, China's public medical institutions terminal yew alcohol sales of more than 7.5 billion yuan, 2020H1 sales of more than 3.5 billion yuan.
Huiyu Pharmaceuticals will harvest the 4th over-evaluation injection.
(Mienet)